Apollo Hospital Share Price Live Updates: Apollo Hospital’s Current Market Position
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and…
Profit by knowlytics
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and…
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and…
Indian stock markets concluded Friday with gains for a third straight session. Benchmark indices Sensex and Nifty 50 closed higher, reflecting positive global sentiment. Bajaj Finance and Bajaj Finserv shares led the gains after strong quarterly earnings reports. Sectoral indices mostly traded higher, with Nifty IT being an exception. Analysts note unusual volatility in global…
India’s microcap segment has significantly outperformed the broader market over the past six months, with the Nifty Microcap 250 index gaining around 17% despite a decline in the Nifty 50. Around 65 microcap stocks surged over 25%, with several delivering multibagger returns.
European shares hit a record high on Friday as a rally in technology stocks, easing crude oil prices and upbeat corporate earnings lifted investor sentiment, helping the STOXX 600 extend its winning streak despite recent central bank decisions and geopolitical tensions.
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and…
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and…
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and…
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and…
Sun Pharma Q1 Results: Sun Pharma reported a 27% YoY rise in Q1 net profit to Rs 2,895 crore, while revenue grew 10% to Rs 15,300 crore, driven by strong performance in India and its innovative medicines business despite weak US formulations sales. EBITDA rose 3% to Rs 4,418 crore. The company highlighted semaglutide approvals…